FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL													
STATEMENT OF CHANGES IN DENEFICIAL	OVVINERSHIP												

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average by	urden							

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MORGAN STANLEY					2. Issuer Name and Ticker or Trading Symbol <u>Cyclacel Pharmaceuticals, Inc.</u> [CYCC]									Relationship of Reporting Person(s) to Issuer (Check all applicable) Director					
(Last) 1585 BR	(Fi OADWAY	rst) (Middle)			3. Date of Earliest Transaction (Month/Day/Year) 08/01/2008								Officer (give title Other (specify below) below)					
(Street) NEW YC (City)			10036 Zip)		4. If	Amen	dment	Date	of Original Filed (Month/Day/Year)					Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tabl	e I - N	on-Deriv	ative	Sec	uritie	s Ac	quire	d, D	isposed o	f, or B	enefic	ially Ow	ned				
Date			2. Transact Date (Month/Day		Execution Date,		3. 4. Securi Transaction Code (Instr. 8) 5)			Acquire (D) (Inst	d (A) or r. 3, 4 and	Securiti Benefic Owned	5. Amount of Securities Beneficially Owned Following		nership Direct Indirect tr. 4)	7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) or (D)	Price	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)	
Common	Stock			08/01/2	800				S		31,200	D	\$1.8	89 1 / 995 1// 1 1 1			By Subsidiary ⁽¹⁾		
Common Stock			08/01/2008				P		31,200	A	\$1.8	9 3,02	3,026,324		I	By Subsidiary ⁽¹⁾			
Common Stock			08/01/2	08/01/2008				S		23,700	D	\$1.8	3,00	3,002,624		I	By Subsidiary ⁽¹⁾		
		Та	ble II								oosed of, convertib				d	,			
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, ecurity or Exercise (Month/Day/Year) if any			4. Transa Code (8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) Amount or Number of		-	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownersl Form: Direct (E or Indire (I) (Instr.	Beneficial Ownership ct (Instr. 4)		

Explanation of Responses:

1. The reported securities are held directly by certain funds (each, a "Fund" and collectively, the "Funds") managed by indirect subsidiary entities of the reporting person. FrontPoint Partners LLC ("FPP"), an indirect wholly owned subsidiary of the reporting person is the parent company of each entity that is the investment manager of one or more of the Funds. This form is filed without prejudice to the reporting person's position that none of the Funds nor FPP or any of its subsidiaries, nor the reporting person, individually or in aggregate, are required to file beneficial ownership reports under Section 16(a) of the a Securities Exchange Act of 1934, and should not be construed or interpreted as a concession or admission that such reports are required.

/s/ Dennine Bullard, By:

Morgan Stanley By: Dennine 08/05/2008

Bullard, Authorized Signatory

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.